Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease
Author:
Affiliation:
1. Indianapolis IN USA
2. La Jolla CA USA
3. Cleveland OH USA
4. New York NY USA
5. Minneapolis MN USA
6. Deerfield IL USA
7. London ON Canada
8. Rochester MN USA
9. Lebanon NH USA
Publisher
Wiley
Subject
Pharmacology (medical),Gastroenterology,Hepatology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.15921/fullpdf
Reference41 articles.
1. Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis;Mao;Aliment Pharmacol Ther,2017
2. Systematic review: monotherapy with antitumour necrosis factor alpha agents versus combination therapy with an immunosuppressive for IBD;Dulai;Gut,2014
3. The safety of vedolizumab for ulcerative colitis and Crohn's disease;Colombel;Gut,2017
4. Retrospective analysis of safety of vedolizumab in patients with inflammatory bowel diseases;Meserve;Clin Gastroenterol Hepatol,2018
5. Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease;Singh;Aliment Pharmacol Ther,2018
Cited by 54 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Comparative Risk of Serious Infection With Vedolizumab vs Anti–Tumor Necrosis Factors in Inflammatory Bowel Disease;American Journal of Gastroenterology;2024-08-19
2. How comparative studies can inform treatment decisions for Crohn’s disease;Expert Opinion on Biological Therapy;2024-08-12
3. Real-world Clinical Effectiveness and Safety of Vedolizumab and Adalimumab in Biologic-naive Patients With Crohn’s Disease;Journal of Clinical Gastroenterology;2024-08-02
4. Comparative Risk of Serious Infection With Vedolizumab vs Anti-Tumor Necrosis Factor in Inflammatory Bowel Disease: Results From Nationwide Swedish Registers;American Journal of Gastroenterology;2024-07-12
5. Is infliximab therapy currently relevant in patients with inflammatory bowel diseases? (review);Koloproktologia;2024-06-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3